| |
Join the lunch and learn on July 17 at 12:30pm PT to hear real-world experiences directly from patients regarding migraine symptoms, treatment and management. Register here. 
|
|
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today! 
|
|
| By Darren Incorvaia,Gabrielle Masson Just as there’s been little relief from the intense heat scorching much of the world this summer, the biotech industry continues to be burned by layoffs. According to the Fierce Biotech Layoff Tracker, there were 38 layoff announcements in the second quarter of 2024, compared to 36 in the same period during 2023. |
|
|
|
By Angus Liu Novo Nordisk’s popular GLP-1 analog semaglutide may be linked to a vision loss disorder, a study suggests. But one team of analysts cautioned against reading too much into the analysis. |
By Nick Paul Taylor Eli Lilly has agreed to buy Morphic for $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda’s injectable inflammatory bowel disease blockbuster Entyvio. |
By Angus Liu After a meeting with the FDA last week, Elevar Therapeutics and Jiangsu Hengrui Pharma are aiming to refile their PD-1 combination around the end of September or October. |
|
Tuesday, July 16, 2024 | 2pm ET / 11am PT Life sciences organizations face many challenges with understanding barriers to patient access, treatment patterns and more. Join us as we dive into five key peer-reviewed studies to gain insights on the crucial role of SDOH in tackling these barriers. Register now. 
|
|
By Nick Paul Taylor Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting the Swiss drugmaker to stop the study and consider changes to the broader program. |
By Conor Hale With a new go-ahead from antitrust regulators in the U.K., Thermo Fisher Scientific is on its way to closing its $3.1 billion deal for Olink, the Swedish developer of protein analyzers, antibody tests and research services. |
By Helen Floersh A new gene editing technique derived from bacterial “jumping genes” can add, remove, recombine and invert DNA sequences, potentially overcoming some of the limitations of CRISPR. |
By Angus Liu Novartis recently said it will propose Bristol Myers Squibb's former chairman and CEO, Giovanni Caforio, to serve as its next board chair in 2025. Fierce Pharma explored the status of the industry's noncompete clauses with experts to learn whether an intercompany transition at the highest levels can proceed without a hitch. |
By Kevin Dunleavy UniQure has sold its commercial viral vector manufacturing facility in Lexington, Mass., to Genezen, which will now supply uniQure’s clinical portfolio and produce CSL Behring’s hemophilia B gene therapy Hemgenix from the site. |
By Angus Liu Pfizer has hired a new oncology commercialization leader from its rival Novartis to help the business reach its goal of marketing eight blockbuster drugs by 2030. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky and Fraiser Kansteiner discuss Fierce’s annual special report, “Big Pharma's 10 highest-paid CEOs.” |
|
|---|
|
|
|
Thursday, July 25, 2024 | 11am ET / 8am PT In the world of clinical trials, the stakes for effective participant recruitment and retention have never been higher. Hear from industry leaders who will highlight the multifaceted barriers that span from regulatory constraints to the critical need for diverse participant representation in this webinar. 
|
|
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper When we talk about digital twins in the context of biology and medicine, we're inherently discussing a simplified model. These simplifications aren't a drawback but a necessity. Sponsored by: Unlearn |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper The Role of Environmental Monitoring in a Contamination Control Strategy Sponsored by: ThermoFisher Scientific |
Whitepaper This study delved into the manufacturing costs of the three mRNA capping methods. It involved discussions with 30 subject matter experts engaged in mRNA therapeutic development across various companies in the US and the EU. Sponsored by: TriLink |
Whitepaper An insider’s workbook filled with practical tips and tools for designing and scaling a global patient support program. Sponsored by: Harte Hanks |
Research Learn how a Top-10 Pharma company automated the extraction of oncology efficacy endpoints from scientific literature with high precision and recall using a combination of AI technologies. Sponsored by: IQVIA |
Whitepaper Small molecule active pharmaceutical ingredients (APIs) continue to grow more complex. Download the white paper to learn more about using synthesis and route design technology to approach API complexity. Sponsored by: Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
